|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心
Jun 28,2023
TAK-931是一種高度特異性的CDC7抑製劑，具有抗腫瘤功效，體內藥效研究通過hjc黄金城進行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一種高度特異性的CDC7抑製劑，具有抗腫瘤功效，體內藥效研究通過hjc黄金城進行
Jun 28,2023
GS-5801是一種有效的KDM5抑製劑，具有抗HBV活性，GS-5801通過hjc黄金城合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一種有效的KDM5抑製劑，具有抗HBV活性，GS-5801通過hjc黄金城合成
Jun 28,2023
QF-036是一種高效的HIV-1抑製劑，具有良好的和藥代動力學特性，PK研究通過hjc黄金城進行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一種高效的HIV-1抑製劑，具有良好的和藥代動力學特性，PK研究通過hjc黄金城進行
Jun 28,2023
設計合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑製劑，PK研究均通過hjc黄金城進行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
設計合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑製劑，PK研究均通過hjc黄金城進行
Jun 28,2023
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過hjc黄金城進行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
查看更多
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過hjc黄金城進行
Jun 28,2023
SKLB-197是一種有效且高度選擇性的ATR抑製劑，PK研究通過hjc黄金城進行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
SKLB-197是一種有效且高度選擇性的ATR抑製劑，PK研究通過hjc黄金城進行
Jun 28,2023
H11-HLE是一種工具分子，可用於研究Fc在介導免疫檢查點治療中的作用，具有抗腫瘤功效
Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.
查看更多
H11-HLE是一種工具分子，可用於研究Fc在介導免疫檢查點治療中的作用，具有抗腫瘤功效
Jun 28,2023
JND003是一種新型選擇性ERRα激動劑，可緩解非酒精性脂肪肝和胰島素抵抗，PK和組織分布測定通過hjc黄金城進行
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.
查看更多
JND003是一種新型選擇性ERRα激動劑，可緩解非酒精性脂肪肝和胰島素抵抗，PK和組織分布測定通過hjc黄金城進行
Jun 28,2023
發現用於局部治療牛皮癬的新型PDE4抑製劑，小鼠、大鼠和人肝微粒體的代謝穩定性實驗通過hjc黄金城測定
Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.
查看更多
發現用於局部治療牛皮癬的新型PDE4抑製劑，小鼠、大鼠和人肝微粒體的代謝穩定性實驗通過hjc黄金城測定
Jun 28,2023
研究用於肺癌和黑色素瘤細胞肺轉移的選擇性PAK4抑製劑的合成，此選擇性PAK4抑製劑的PK研究通過hjc黄金城進行
The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.
查看更多
研究用於肺癌和黑色素瘤細胞肺轉移的選擇性PAK4抑製劑的合成，此選擇性PAK4抑製劑的PK研究通過hjc黄金城進行